Evidence of a dual mechanism of action underlying the anti-proliferative and cytotoxic effects of ammonium-alkyloxy-stilbene-based α7- and α9-nicotinic ligands on glioblastoma cells.


Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
01 2022
Historique:
received: 05 08 2021
revised: 27 09 2021
accepted: 23 10 2021
pubmed: 11 11 2021
medline: 19 3 2022
entrez: 10 11 2021
Statut: ppublish

Résumé

Glioblastomas (GBMs), the most frequent brain tumours, are highly invasive and their prognosis is still poor despite the use of combination treatment. MG624 is a 4-oxystilbene derivative that is active on α7- and α9-containing neuronal nicotinic acetylcholine receptor (nAChR) subtypes. Hybridisation of MG624 with a non-nicotinic resveratrol-derived pro-oxidant mitocan has led to two novel compounds (StN-4 and StN-8) that are more potent than MG624 in reducing the viability of GBM cells, but less potent in reducing the viability of mouse astrocytes. Functional analysis of their activity on α7 receptors showed that StN-4 is a silent agonist, whereas StN-8 is a full antagonist, and neither alters intracellular [Ca

Identifiants

pubmed: 34756924
pii: S1043-6618(21)00543-0
doi: 10.1016/j.phrs.2021.105959
pii:
doi:

Substances chimiques

Ammonium Compounds 0
Antineoplastic Agents 0
CHRNA9 protein, human 0
Ligands 0
Reactive Oxygen Species 0
Receptors, Nicotinic 0
Stilbenes 0
alpha7 Nicotinic Acetylcholine Receptor 0
Adenosine Triphosphate 8L70Q75FXE
AKT1 protein, human EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105959

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Susanna Pucci (S)

CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy.

Cristiano Bolchi (C)

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20129 Milano, Italy.

Francesco Bavo (F)

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20129 Milano, Italy.

Marco Pallavicini (M)

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20129 Milano, Italy.

Clara De Palma (C)

Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.

Massimiliano Renzi (M)

Dipartimento di Fisiologia e Farmacologia, Sapienza Università di Roma, 00185 Roma, Italy.

Sergio Fucile (S)

Dipartimento di Fisiologia e Farmacologia, Sapienza Università di Roma, 00185 Roma, Italy; I.R.C.C.S. Neuromed, Via Atinese 18, 86077 Pozzilli, Italy.

Roberta Benfante (R)

CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.

Simona Di Lascio (S)

Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.

Donatella Lattuada (D)

Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.

Jean-Louis Bessereau (JL)

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, Lyon, France.

Manuela D'Alessandro (M)

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, Lyon, France.

Valerie Risson (V)

Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, Lyon, France.

Michele Zoli (M)

Department of Biomedical, Metabolic and Neural Sciences, Center for Neuroscience and Neurotechnology (CfNN), University of Modena and Reggio Emilia, 41125 Modena, Italy.

Francesco Clementi (F)

CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.

Cecilia Gotti (C)

CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy. Electronic address: cecila.gotti@in.cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH